
-
Amylyx Pharmaceuticals NasdaqGS:AMLX Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. Its lead products candidate includes avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Location: 43 Thorndike Street, Cambridge, MA, 02141, United States | Website: https://amylyx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
234.1M
Cash
204.1M
Avg Qtr Burn
-51.75M
Short % of Float
8.93%
Insider Ownership
12.47%
Institutional Own.
85.84%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Relyvrio (AMX0035) Details Amyotrophic lateral sclerosis | Approved Update | |
Avexitide Details Post-Bariatric Hypoglycemia (PBH) | Phase 3 Data readout | |
AMX0035 Details Progressive supranuclear palsy | Phase 3 Data readout | |
Relyvrio (AMX0035) Details Amyotrophic lateral sclerosis | Phase 3 Update | |
AMX0035 Details Alzheimer's disease | Phase 2 Update | |
AMX0035 Details Wolfram syndrome | Phase 2 Update | |
AMX0114 Details Amyotrophic lateral sclerosis | Phase 1 Data readout |